An observational study in Vascular Diseases, Patient Empowerment and Patient Satisfaction, sponsored by Cardiff and Vale University Health Board. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Cardiff and Vale University Health Board · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Vascular Diseases with a site in United Kingdom — 12 open to participants now, 17 under way, 2 of them phase 3. Vascular Diseases · United Kingdom.
Among the 62 studies in Vascular Diseases with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2024, is one of 19 observational ones, reaches primary completion later than 5 of the 16 other live ones, and was the 58th registered.
694 studies on the registry are indexed under Vascular Diseases; 127 are open to participants now.
Browse Vascular Diseases studies →12 of the 62 studies in Vascular Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Fundación EPIC · Sites in United Kingdom, United States, Belgium and 1 more country
Ages 18–85
Medtronic Vascular · Sites in United Kingdom, Australia, Belgium and 6 more countries
Ages 18+
W.L.Gore & Associates · Sites in United Kingdom, United States, Denmark and 7 more countries
Ages 18+
AliveCor · Sites in United Kingdom, United States
Ages 18+ · Healthy volunteers
Cook Research Incorporated · Sites in United Kingdom, United States
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 95 Vascular Diseases studies recruiting now, 59 (62%) set no upper age limit and 13 (14%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 8 · Phase 4 3
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 200 across 217 observational studies indexed under Vascular Diseases.
Median enrollment 120 across the 43 interventional studies, 200 across the 19 observational. Of the 37 that completed or were terminated, 9 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 62 have an industry lead sponsor. The 10 most frequent:
Cardiff and Vale University Health Board is the lead sponsor of 44 studies on the registry; 8 are open to participants now.
Cardiff and Vale University Health Board has 1 study filed under Vascular Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Vascular Diseases with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04875429Cook Research IncorporatedZenith® Fenestrated+ Clinical Study | 2026-11 |
| NCT06271577AliveCorSmartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II | 2026-12 |
| NCT07115953Medtronic VascularStreamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension | 2027-10-30 |
| NCT06187012University of OxfordHypertension Explored in Long-term Postpartum Follow-up in Later Life | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 62 studies in Vascular Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
THE PROBLEM:
Patient Reported Experience Measures (PREMs) ask patients about their healthcare service experience. It gives them a voice to share their views. PREMs allow healthcare providers (HCPs) to see where care is good, and where they could improve. Vascular surgery is a surgical speciality looking after people's blood vessels (arteries and veins).
There is no PREM available for vascular patients. The research team want to create a PREM for this patient group.
WHY IT IS IMPORTANT:
A PREM allows HCPs to record and understand patients' experiences of their treatment. It gives patients a way to provide feedback on their healthcare experience. PREMs can help HCPs make changes to patients' care, identifying areas of good practice and areas for improvement. The Welsh Government is keen to support the use of PREMs.
AIMS:
To develop a PREM specific to vascular surgery patients.
RESEARCH PLAN:
The research team will summarise the literature about PREMs in surgery. The research team will then run focus groups and interviews with patients and staff to create a 'draft' PREM for vascular patients in Wales. The 'draft' PREM will be translated into Welsh.
In the second phase, a larger number of vascular patients (100-300 depending on how long the 'draft' PREM is) from hospitals across Wales will complete the questionnaire. Statistical tests will look at the results to see if the questionnaire works well to capture patients' experiences. Based on these results, small changes will be made to make the 'draft' PREM better. This will make sure the 'final PREM' is ready for widespread use in Wales and beyond.
PATIENT AND PUBLIC INVOLVEMENT:
The patients' experience team at CAVUHB has reviewed our patients' materials. Our research team includes PPI co-applicants (DC and AH). DC a double amputee who has had many vascular operations. DC has experience raising awareness about vascular disease through public forums like the Limbless Association Charity and BBC Radio Wales. AH has issues with her leg due to smoking and had a keyhole operation to help with that. She had some problems after the procedure This is her first time as a PPI representative. DC and AH supported our research design and will be steering group members. Also, our research focuses on giving patients a voice and will include patients across Wales. A diverse group of patients will be involved across all stages of the PREM development.
Background: PREMs have emerged as instruments designed to capture patients' experiences of their healthcare journey. No PREMs have been developed or validated to be used among vascular surgery patients specifically.
Objectives: To develop and validate a PREM specific to vascular surgery, assessing the patient's experience and satisfaction with their care and treatment.
Study design and methods: Patient Reported Experience Measures In Vascular Surgery Enhancement Study (PREMIERE) is a multi-site sequential mixed-methods cohort design, incorporating qualitative and quantitative approaches in two phases. The first phase will focus on developing a draft PREM for vascular surgery patients, while the second phase will aim to validate the draft PREM to create a 'final PREM'. Patient inclusion criteria are: (i) age ≥18 ; (ii) have undergone a vascular procedure (iii) experienced an inpatient vascular care within the previous 3 months; (iv) not cognitively impaired; (v) willing and able to provide written consent for participation; (vi) able to communicate in English or Welsh.
Statistical analysis: For the qualitative phase, inductive thematic analysis will be carried out using the non-numerical data analysis for Windows software NVivo . For quantitative data, psychometric tests such as item analysis, internal consistency, construct validity, and principal component analysis with varimax rotation will be used to extract factors. Quantitative data will be analysed using IBM SPSS Statistics (Version 27) software.
Anticipated impact: PREMIERE will contribute to the development of a robust and context-specific PREM for vascular patients. This PREM will provide a valuable tool for assessing and improving the in-patient vascular surgery pathway, including pre-operative, peri-operative, and post-operative phases. Also, the utilization of a robust vascular PREM presents a transformative opportunity to benchmark and enhance the performance of vascular units.
Patients undergoing in-patient vascular care, which involves specialized vascular surgery for hospital-admitted individuals, including those recently discharged with conditions like peripheral artery disease. Recruitment will engage patients preoperatively and post-service (within 1-3 months) to minimize bias. The study will target UK's central vascular units for diverse patient demographics. Consistent eligibility criteria will apply to both study phases (development and validation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Degree of Validity of the PREM
Validity: The extent to which a measure assesses what it intends to measure.
Time frame: Day 0, Day 30
Degree of Reliability of the PREM
Reliability: The consistency and stability of a measure over time and across different conditions.
Time frame: Day 0, Day 30
Degree of Responsiveness of the PREM
Responsiveness: The ability of a measure to detect change over time in the concept being measured.
Time frame: Day 0, Day 30
Degree of Feasibility of implementing the PREM in clinical practice
Feasibility: The practicality and suitability of implementing a measure in a specific setting or context.
Time frame: Day 0, Day 30
Plan to share: No — The full dataset is not expected to be made available for secondary research. In accordance with standard measures to prevent statistical disclosure, quantitative data relating to five or fewer individuals will be aggregated or redacted prior to publication. Similarly, full focus group transcripts will not be made available to external individuals or organisations due to the possibility of statistical disclosure from these qualitative data.
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Aug 2025, 14 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiff and Vale University Health Board